ABBISKO-B (02256) affiliate Glory Pharmaceuticals has completed the first dose of patient in the Phase 1 clinical trial of the innovative PRMT5*MTA inhibitor ABSK131.
Hoyu Group B (02256) announces that its subsidiary, Shanghai Hoyu Biomedical Technology Co., Ltd. (Hoyu Medical...
ABBISKO-B (02256) announced that its subsidiary, Shanghai Heyu Biomedical Technology Co., Ltd. (Heyu Medicine) announced that its research-based innovative PRMT5*MTA inhibitor ABSK131 has completed the first patient dosing in a phase 1 clinical trial in patients with MTAP-deficient advanced/metastatic solid tumors. In March 2025, ABSK131 received IND approval from the China National Medical Products Administration Drug Evaluation Center. In December 2024, ABSK131 received IND approval from the US Food and Drug Administration.
Related Articles
Global Markets Rally on U.S.–Japan Trade Agreement
PNC Teams Up With Coinbase: Why Main-Street Banking Just Flipped the Switch on Everyday Crypto Trading
RECBIO-B(02179) received approval from the China Securities Regulatory Commission for a targeted issuance of domestic shares.
Global Markets Rally on U.S.–Japan Trade Agreement
PNC Teams Up With Coinbase: Why Main-Street Banking Just Flipped the Switch on Everyday Crypto Trading
RECBIO-B(02179) received approval from the China Securities Regulatory Commission for a targeted issuance of domestic shares.
RECOMMEND
Backed by BYD, Why Has the Leading EV Charger Firm Seen Revenue Declines and Surging Losses?
23/07/2025
Just Days Away from Losing Tens of Millions of Dollars! Copper-Laden Ships Race Toward U.S. Ports
23/07/2025
Japan "Surrenders"? Trump Claims "U.S. and Japan Reach Deal: Japan Accepts 15% Tariff Rate, Opens Auto and Rice Markets, Pledges $550 Billion in U.S. Investments"
23/07/2025
